PERTUZUMAB

Brand name:

• Perjeta®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory or early stage breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to existing listing (Standard Re-entry Pathway)

Comment:

--

Submission sponsor:

ROCHE PRODUCTS PTY LTD

Other PBAC consideration:

• PERTUZUMAB

Submission received for:

March 2025 PBAC meeting

Opportunity for consumer comment:

Open 27/11/2024 and close 29/01/2025 (see PBS Website)

PBAC meeting:

Held on 12/03/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

06/03/2026

5Lodgement of required documentation:

17/03/2026

Acceptance of complete documentation:

Under consideration

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---